[1] 伊丹丹,黄韬,宋鹏,等.甲状腺微小乳头状癌手术方式对肿瘤复发影响的meta分析[J].东南大学学报:医学版,2017,36(1):48-52.
[2] DAVIES L,WELCH H G.Current thyroid cancer trends in the United States[J].JAMA Otolaryngol Head Neck Surg,2014,140(4):317-322.
[3] LAWRENCE M S,STOJANOV P,POLAK P,et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J].Nature,2013,499(7457):214-218.
[4] Cancer Genome Atlas Research Network.Integrated genomic characterization of papillary thyroid carcinoma[J].Cell,2014,159(3):676-690.
[5] MONTERO-CONDE C,RUIZ-LLORENTE S,DOMINGUEZ J M,et al.Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas[J].Cancer Discov,2013,3(5):520-533.
[6] LITO P,PRATILAS C A,JOSEPH E W,et al.Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas[J].Cancer Cell,2012,22(5):668-682.
[7] POULIKAKOS P I,ZHANG C,BOLLAG G,et al.RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF[J].Nature,2010,464(7287):427-430.
[8] SABRA M M,DOMINGUEZ J M,GREWAL R K,et al.Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases[J].J Clin Endocrinol Metab,2013,98(5):E829-836.
[9] HO A L,GREWAL R K,LEBOEUF R,et al.Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer[J].N Engl J Med,2013,368(7):623-632.
[10] NIKIFOROV Y E,SEETHALA R R,TALLINI G,et al.Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma:a paradigm shift to reduce overtreatment of indolent tumors[J].JAMA Oncol,2016,2(8):1023-1029.
[11] RABES H M,DEMIDCHIK E P,SIDOROW J D,et al.Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas:biological,phenotypic,and clinical implications[J].Clin Cancer Res,2000,6(3):1093-1103.
[12] GUDMUNDSSON J,SULEM P,GUDBJARTSSON D F,et al.Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations[J].Nat Genet,2009,41(4):460-464.
[13] GARA S K,JIA L,MERINO M J,et al.Germline HABP2 mutation causing familial nonmedullary thyroid cancer[J].N Engl J Med,2015,373(5):448-455.
[14] SAHASRABUDHE R,ESTRADA A,LOTT P,et al.The 8q24 rs6983267G variant is associated with increased thyroid cancer risk[J].Endocr Relat Cancer,2015,22(5):841-849.
[15] TOMSIC J,FULTZ R,LIYANARACHCHI S,et al.HABP2 G534E variant in papillary thyroid carcinoma[J].PLoS One,2016,11(1):e0146315.
[16] SOBRINHO-SIMÖES M,ELOY C,MAGALHÄES J,et al.Follicular thyroid carcinoma[J].Mod Pathol,2011,24(Suppl 2):S10-18.
[17] LANDA I,GANLY I,CHAN T A,et al.Frequent somatic TERT promoter mutations in thyroid cancer:higher prevalence in advanced forms of the disease[J].J Clin Endocrinol Metab,2013,98(9):E1562-1566.
[18] CIBAS E S,ALI S Z.The bethesda system for reporting thyroid cytopathology[J].Am J Clin Pathol,2009,132(5):658-665.
[19] SANTHANAM P,KHTHIR R,GRESS T,et al.Gene expression classifier for the diagnosis of indeterminate thyroid nodules:a meta-analysis[J].Med Oncol,2016,33(2):14.
[20] NIKIFOROV Y E,CARTY S E,CHIOSEA S I,et al.Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology[J].Thyroid,2015,25(11):1217-1223.
[21] HAUGEN B R,ALEXANDER E K,BIBLE K C,et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].Thyroid,2016,26(1):1-133.
[22] ODA H,MIYAUCHI A,ITO Y,et al.Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery[J].Thyroid,2016,26(1):150-155.
[23] TUTTLE R M,TALA H,SHAH J,et al.Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation:using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system[J].Thyroid,2010,20(12):1341-1349.
[24] XING M,ALZAHRANI A S,CARSON K A,et al.Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J].J Clin Oncol,2015,33(1):42-50.
[25] HUANG F W,HODIS E,XU M J,et al.Highly recurrent TERT promoter mutations in human melanoma[J].Science,2013,339(6122):957-959.
[26] XING M,LIU R,LIU X,et al.BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence[J].J Clin Oncol,2014,32(25):2718-2726.
[27] HAY I D,LEE R A,DAVIDGE-PITTS C,et al.Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected "recurrent" neck nodal metastases in 25 patients with TNM stages Ⅲ or Ⅳ A papillary thyroid carcinoma previously treated by surgery and 131I therapy[J].Surgery,2013,154(6):1448-1454.
[28] TUFANO R P,CLAYMAN G,HELLER K S,et al.Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer:a critical review of the risks and benefits of surgical intervention versus active surveillance[J].Thyroid,2015,25(1):15-27.
[29] SCHVARTZ C,BONNETAIN F,DABAKUYO S,et al.Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients[J].J Clin Endocrinol Metab,2012,97(5):1526-1535.
[30] SCHLUMBERGER M,CATARGI B,BORGET I,et al.Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J].N Engl J Med,2012,366(18):1663-1673.
[31] WANG W,LARSON S M,TUTTLE R M,et al.Resistance of[18f]-fluorodeoxyglucoseavid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine[J].Thyroid,2001,11(12):1169-1175.
[32] ROTHENBERG S M,MCFADDEN D G,PALMER E L,et al.Redifferentiation of iodine-refractory BRAF V600 Emutant metastatic papillary thyroid cancer with dabrafenib[J].Clin Cancer Res,2015,21(5):1028-1035.
[33] ORITA Y,SUGITANI I,TODA K,et al.Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma[J].Thyroid,2011,21(1):31-35.
[34] SCHLUMBERGER M,TAHARA M,WIRTH L J,et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J].N Engl J Med,2015,372(7):621-630.
[35] BROSE M S,NUTTING C M,JARZAB B,et al.Sorafenib in radioactive iodine-refractory,locally advanced or metastatic differentiated thyroid cancer:a randomised,double-blind,phase 3 trial[J].Lancet,2014,384(9940):319-328.
[36] DUNN L,FAGIN J A.Therapy:lenvatinib and radioiodine-refractory thyroid cancers[J]. Nat Rev Endocrinol,2015,11(6):325-327.
[37] BIBLE K C,SUMAN V J,MOLINA J R,et al.Efficacy of pazopanib in progressive,radioiodine-refractory,metastatic differentiated thyroid cancers:results of a phase 2 consortium study[J].Lancet Oncol,2010,11(10):962-972.
[38] HICK A C,DELMARCELLE A S,BOUQUET M,et al.Reciprocal epithelial:endothelial paracrine interactions during thyroid development govern follicular organization and C-cells differentiation[J].Dev Biol,2013,381(1):227-240.
[39] JAIN R K.Antiangiogenesis strategies revisited:from starving tumors to alleviating hypoxia[J].Cancer Cell,2014,26(5):605-622.
[40] LANDA I,IBRAHIMPASIC T,BOUCAI L,et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers[J].J Clin Invest,2016,126(3):1052-1066.
[41] CHAPMAN P B,HAUSCHILD A,ROBERT C,et al.Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J].N Engl J Med,2011,364(26):2507-2516.
[42] TIACCI E,PARK J H,de CAROLIS L,et al.Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia[J].N Engl J Med,2015,373(18):1733-1747.
[43] KOPETZ S,DESAI J,CHAN E,et al.Phase Ⅱ pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer[J] J Clin Oncol,2015,33(34):4032-4038.
[44] BROSE M S,CABANILLAS M E,COHEN E E,et al.Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine:a non-randomised,multicentre,open-label,phase 2 trial[J].Lancet Oncol,2016,17(9):1272-1282.
[45] 刘军,苏磊,桑剑锋,等.颈部低位领式切口行甲状腺癌择区性颈清扫的临床应用[J].东南大学学报:医学版,2015,34(4):572-576. |
